摘要
目的:探讨黄芪经正常、肝纤维化机体代谢后血清内黄芪甲苷含量差别,及其对肝纤维化发生中HSCs活化增殖的影响。方法:40%CCl4,皮下注射9周制备大鼠肝纤维化模型。正常、肝纤维化大鼠分别灌服黄芪,提取正常、肝纤维大鼠药物血清,HPLC检测药物血清内黄芪甲苷含量。CCK-8法检测黄芪甲苷对HSCs增殖影响,3-Pro掺入-胶原酶消化法检测黄芪甲苷对HSCs胶原分泌的影响。结果:正常、病理药物血清内均可检出黄芪甲苷。病理药物血清内黄芪甲苷含量高于正常药物血清(0.1140 vs0.0851,P<0.05)。黄芪甲苷可抑制HSCs增殖及I型胶原分泌。结论:机体状态可影响黄芪内有效成分黄芪甲苷的代谢,可能与肝脏不同状态、口服药物首过效应及分解代谢有关。HPLC可用于检测中药体内有效成分含量,评估机体代谢对于中药有效成分含量的影响及临床药效。黄芪甲苷可有效抑制HSCs增殖、活化,为抗肝纤维化有效作用成分之一。
Objective : To detect the contents of astragaloside Ⅳ in raw astragalus mongholicus, and the corresponding drug sera ( normal and fibrotic drug sera) by HPLC. To compare the astragaloside Ⅳ in astragalus mongholicus. To study the effects of astragaloside Ivon proliferation and activation of HSCs in hepatic fibrogenesis. Methods : Inducing liver fibrosis in rats by 40% CCI,, SC, for 9 weeks. Astragalus mongholicus, solutions were given to the normal and fibrotic rats, respectively for 5days. Normal and fibrotic drug sera from rats were extracted. The separation of astragaloside Ivwas performed by HPLC. The effects of astragaloside Ⅳ on the proliferation of HSCs were measured by the method of CCK - 8 (Cell Counting Kit - 8). The effects on synthesis of collagen I were assessed by 3H - proline incorporation assays. Results : Astragaloside Ⅳ could be found both in normal and fibrotic drug sera. The contents of astragaloside Ⅳ in fibrotic drug sera were higher than normal drug sera (0.1140 vs 0.0851, P 〈0.05 ). Astragaloside Ⅳ had inhibitory effect on proliferation of HSCs and the synthesis of collagen I in HSCs. Conclusion : HPLC is suitable for the determination of bioactive components in drugs (especially Traditional Chinese Medicine, TCM) in vitro and after metabolized in vivo under different conditions. The results show that astragaloside Ⅳ could be found in both raw astragalus mongholicus and its corresponding drug sera. The different conditions for metabolism might affect the contents of astragalosideⅣ. The concentration of Astragaloside Ⅳ in fibrotic drug sera is higher than that in normal sera, which may be caused by different "first pass effect" under different liver conditions and the different analytic metabolism. This phenomenon is in accordance with the different curative effects of different patients accepting TCM in clinic. Astragaloside Ⅳ, which could inhibit the proliferation and activation of HSCs, might be a working component in astragalus mongholicus.
出处
《中华中医药学刊》
CAS
2011年第12期2770-2773,共4页
Chinese Archives of Traditional Chinese Medicine
关键词
黄芪甲苷
血清药理学
高效液相色谱法
肝纤维化
肝星状细胞
Astragaloside Ⅳ
Seropharmacological method
High performance liquid chromatography ( HPLC )
Liver fibrosis
Hepatic stellate cells (HSCs)